Zheng Min

Zhengzhou Minzhong Pharmaceutical Co., Ltd., established in 1994, is a prominent Chinese pharmaceutical company specializing in the research, production, and global distribution of semi-synthetic antibiotic Active Pharmaceutical Ingredients (APIs), specifically the Rifamycin series. The company is a leader in the manufacturing of critical antibiotics such as Rifampicin, Rifamycin Sodium, Rifaximin, Rifabutin, and Rifapentine, which are essential for treating tuberculosis and other bacterial diseases. Operating from state-of-the-art GMP-certified facilities in Zhengzhou and a newly opened production base in Kaifeng, the company serves pharmaceutical clients in over 30 countries worldwide. Zhengzhou Minzhong is recognized as a High-Tech Enterprise and has independently developed patented manufacturing processes, including a novel method for Rifapentine production. Its commitment to quality and innovation has established it as a key supplier in the global infectious disease therapeutic market.